Celldex Therapeutics (NASDAQ:CLDX) Receives Buy Rating from HC Wainwright

Celldex Therapeutics (NASDAQ:CLDX)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research note issued to investors on Friday,Benzinga reports. They currently have a $80.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price target suggests a potential upside of 293.89% from the company’s current price.

A number of other analysts also recently issued reports on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $67.00 price target on shares of Celldex Therapeutics in a report on Wednesday, January 29th. UBS Group started coverage on Celldex Therapeutics in a report on Thursday, February 13th. They issued a “buy” rating and a $44.00 target price on the stock. Two analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $56.50.

Celldex Therapeutics Price Performance

NASDAQ:CLDX opened at $20.31 on Friday. The firm’s 50-day moving average price is $23.95 and its 200-day moving average price is $29.04. The company has a market capitalization of $1.35 billion, a PE ratio of -7.90 and a beta of 1.60. Celldex Therapeutics has a 1-year low of $20.25 and a 1-year high of $53.18.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.02. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. Equities analysts anticipate that Celldex Therapeutics will post -2.48 EPS for the current fiscal year.

Hedge Funds Weigh In On Celldex Therapeutics

Hedge funds have recently made changes to their positions in the business. Wellington Management Group LLP lifted its holdings in Celldex Therapeutics by 14.5% in the 3rd quarter. Wellington Management Group LLP now owns 9,243,599 shares of the biopharmaceutical company’s stock worth $314,190,000 after purchasing an additional 1,167,659 shares in the last quarter. Vanguard Group Inc. grew its holdings in Celldex Therapeutics by 0.3% during the 4th quarter. Vanguard Group Inc. now owns 3,881,995 shares of the biopharmaceutical company’s stock valued at $98,098,000 after buying an additional 12,213 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Celldex Therapeutics by 23.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,557,136 shares of the biopharmaceutical company’s stock valued at $89,890,000 after buying an additional 676,771 shares during the last quarter. Bellevue Group AG lifted its holdings in shares of Celldex Therapeutics by 3.4% in the third quarter. Bellevue Group AG now owns 3,071,615 shares of the biopharmaceutical company’s stock worth $104,404,000 after buying an additional 100,000 shares in the last quarter. Finally, Point72 Asset Management L.P. boosted its position in shares of Celldex Therapeutics by 50.8% during the fourth quarter. Point72 Asset Management L.P. now owns 2,515,972 shares of the biopharmaceutical company’s stock worth $63,579,000 after acquiring an additional 847,264 shares during the last quarter.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.